Regenerative Therapy After Cancer: What Are the Risks?

Donnenberg, Vera S.; Zimmerlin, Ludovic; Rubin, J. Peter; Donnenberg, Albert D.

doi:10.1089/ten.teb.2010.0352

Cited by 94 publications

(72 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The adipose-derived cell's immunomodulatory and immunosuppressive properties present additional concerns. Recent reports document the ability of ASCs to promote the proliferation of active breast cancer cells in vitro and in vivo via paracrine mechanisms [38][39][40][41][42]. Comparable studies indicate that ASCs promote the growth of prostate cancer cell lines transplanted into immunodeficient mice [43].…”

Section: Tumorigenesismentioning

confidence: 99%

“…While there is a promise that this homing property can be exploited by using transduced or transfected bone marrow MSCs as antitumor delivery vehicles, this, nevertheless, remains a potential risk [45]. This has particular relevance with respect to the expanded use of SVF cells and ASCs for postmastectomy reconstruction in breast cancer patients [38,42]. Consequently, additional preclinical studies evaluating SVF cells and ASCs interactions with a wider range of tumor types should be undertaken in the near future.…”

Section: Tumorigenesismentioning

confidence: 99%

“…While some plastic surgeons have experienced successful outcomes with fat grafting approaches, adverse events including cyst formation, fat necrosis, and microcalcifications have been observed in a percentage of breast reconstructions [50][51][52]. In addition, the immunosuppressive and tumor promoting functions of SVF cells and ASCs leads to concerns that their introduction into the breast tissue of a postmastectomy patient could enhance the recurrent growth of residual cancer cells [38]. Consequently, plastic surgeons and related clinical practitioners remain cautious concerning the use of adipose-derived cells in the context of cancer patients at this time [53].…”

Section: Clinical Studies-are We There Yet? Clinical Opportunitiesmentioning

confidence: 99%

See 2 more Smart Citations

Concise Review: Adipose-Derived Stromal Vascular Fraction Cells and Stem Cells: Let's Not Get Lost in Translation

et al. 2011

View full text Add to dashboard Cite

Subcutaneous fat has emerged as an alternative tissue source for stromal/stem cells in regenerative medicine. Over the past decade, international research efforts have established a wealth of basic science and preclinical evidence regarding the differentiation potential and regenerative properties of both freshly processed, heterogeneous stromal vascular fraction cells and culture expanded, relatively homogeneous adipose-derived stromal/stem cells. The stage has been set for clinicians to translate adipose-derived cells from the bench to the bedside; however, this process will involve “development” steps that fall outside of traditional “hypothesis-driven, mechanism-based” paradigm. This concise review examines the next stages of the development process for therapeutic applications of adipose-derived cells and highlights the current state of the art regarding clinical trials. It is recommended that the experiments addressing these issues be reported comprehensively in the peer-review literature. This transparency will accelerate the standardization and reproducibility of adipose-derived cell therapies with respect to their efficacy and safety.

show abstract

Section: Tumorigenesismentioning

confidence: 99%

Section: Tumorigenesismentioning

confidence: 99%

Section: Clinical Studies-are We There Yet? Clinical Opportunitiesmentioning

confidence: 99%

See 1 more Smart Citation

Concise Review: Adipose-Derived Stromal Vascular Fraction Cells and Stem Cells: Let's Not Get Lost in Translation

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Based on the unique homing capability of tissue-derived MSCs to stroma of various primary and metastatic cancers (3)(4)(5)(6), MSCs have the potential to treat or even eliminate various cancers by delivering various anticancer agents (7)(8)(9). Because of their potential for differentiation (10,11) and production of immunomodulatory, angiogenic, anti-apoptotic, anti-scarring, and prosurvival factors (12), MSCs have shown promising regeneration potential after radical cancer treatment in animal models, such as soft tissue reconstruction after disfiguring surgeries for head, neck, or breast cancers (13) and salivary gland regeneration for head and neck cancer patients treated with radiotherapy (14,15). As one example, the combination of osteogenic potential and targeted delivery of anticancer agents make MSCs a promising option to treat tumor-induced osteolysis (16,17).…”

mentioning

confidence: 99%

MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs

Zhao¹,

Gregory²,

Lee³

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

141

139

View full text Add to dashboard Cite

Mesenchymal stem or stromal cells (MSCs) have many potential therapeutic applications including therapies for cancers and tissue damages caused by cancers or radical cancer treatments. However, tissue-derived MSCs such as bone marrow MSCs (BM-MSCs) may promote cancer progression and have considerable donor variations and limited expandability. These issues hinder the potential applications of MSCs, especially those in cancer patients. To circumvent these issues, we derived MSCs from transgene-free human induced pluripotent stem cells (iPSCs) efficiently with a modified protocol that eliminated the need of flow cytometric sorting. Our iPSC-derived MSCs were readily expandable, but still underwent senescence after prolonged culture and did not form teratomas. These iPSC-derived MSCs homed to cancers with efficiencies similar to BM-MSCs but were much less prone than BM-MSCs to promote the epithelial-mesenchymal transition, invasion, stemness, and growth of cancer cells. The observations were probably explained by the much lower expression of receptors for interleukin-1 and TGFβ, downstream protumor factors, and hyaluronan and its cofactor TSG6, which all contribute to the protumor effects of BM-MSCs. The data suggest that iPSC-derived MSCs prepared with the modified protocol are a safer and better alternative to BM-MSCs for therapeutic applications in cancer patients. The protocol is scalable and can be used to prepare the large number of cells required for "off-the-shelf" therapies and bioengineering applications.

show abstract

“…Entretanto, apesar desta série de benefícios, alguns estudos sugerem que ASC quando cultivadas possam aumentar o crescimento de células tumorais ativas (126) , o que gera preocupações quanto ao seu uso, por exemplo, dentro do tecido mamário após mastectomias (127) , principalmente quando o cultivo envolve passagens superiores a quatro meses (128) .…”

Section: Estratégias Para Aumentar a Sobrevida Dos Enxertos De Gorduraunclassified

Ensaio clínico randomizado sobre o uso de enxerto autógeno de gordura suplementado com células estromais derivadas do tecido adiposo para a reconstrução de partes moles faciais em pacientes portadores de microssomia craniofacial

Tanikawa¹

View full text Add to dashboard Cite

Regenerative Therapy After Cancer: What Are the Risks?

Cited by 94 publications

References 110 publications

Concise Review: Adipose-Derived Stromal Vascular Fraction Cells and Stem Cells: Let's Not Get Lost in Translation

Concise Review: Adipose-Derived Stromal Vascular Fraction Cells and Stem Cells: Let's Not Get Lost in Translation

MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs

Ensaio clínico randomizado sobre o uso de enxerto autógeno de gordura suplementado com células estromais derivadas do tecido adiposo para a reconstrução de partes moles faciais em pacientes portadores de microssomia craniofacial

Contact Info

Product

Resources

About